{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["108"],"submitter":["Chen B"],"funding":["Shanghai Municipal Health Commission"],"pubmed_abstract":["<h4>Background</h4>Jingyin granules (JY), one patented Chinese herbal formula, have been advised for treating coronavirus disease 2019 (COVID-19) in China. As of now, the safety and effectiveness of JY in treating COVID-19 patients were still to be evaluated.<h4>Purpose</h4>To investigate the safety and clinical effectiveness of JY in treating mild COVID-19 patients.<h4>Study design</h4>We carried out a prospective cohort study, as the highly infectious COVID-19 omicron variant ranged in Shanghai (ClinicalTrial.gov registration number: ChiCTR2200058692).<h4>Methods</h4>Participants infected with COVID-19, who were diagnosed as mild cases, were assigned to receive either JY (JY group) or traditional Chinese medicine placebo (placebo group) orally for 7 days. The primary clinical indicators "],"journal":["Phytomedicine : international journal of phytotherapy and phytopharmacology"],"pagination":["154496"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9575312"],"repository":["biostudies-literature"],"pubmed_title":["Clinical efficacy of Jingyin granules, a Chinese patent medicine, in treating patients infected with coronavirus disease 2019."],"pmcid":["PMC9575312"],"pubmed_authors":["Shen J","Huang W","Lyu H","Gao Y","Zhang L","Fang M","Chen B","Yuan W","Yu X","Li M","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Clinical efficacy of Jingyin granules, a Chinese patent medicine, in treating patients infected with coronavirus disease 2019.","description":"<h4>Background</h4>Jingyin granules (JY), one patented Chinese herbal formula, have been advised for treating coronavirus disease 2019 (COVID-19) in China. As of now, the safety and effectiveness of JY in treating COVID-19 patients were still to be evaluated.<h4>Purpose</h4>To investigate the safety and clinical effectiveness of JY in treating mild COVID-19 patients.<h4>Study design</h4>We carried out a prospective cohort study, as the highly infectious COVID-19 omicron variant ranged in Shanghai (ClinicalTrial.gov registration number: ChiCTR2200058692).<h4>Methods</h4>Participants infected with COVID-19, who were diagnosed as mild cases, were assigned to receive either JY (JY group) or traditional Chinese medicine placebo (placebo group) orally for 7 days. The primary clinical indicators ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-04T19:41:23.687Z","creation":"2025-02-19T01:40:53.14Z"},"accession":"S-EPMC9575312","cross_references":{"pubmed":["36288651"],"doi":["10.1016/j.phymed.2022.154496"]}}